Partnership Opportunities 

In addition to its in-licensing activities, the company is pursuing alliances based on its proprietary products and platforms to:

• Develop and commercialize the anti-CD32B monoclonal antibody MGA321.
• Develop and commercialize Dual Affinity ReTargeting (DART) products.
• Engineer and develop proprietary and next generation antibodies with enhanced function by engineering their Fc regions.
• Develop follow-on/biosimilar monoclonal antibody products.
• Develop and commercialize West Nile Virus monoclonal antibody MGAWN1.

To inquire about partnership opportunities with MacroGenics, please contact:

Business Development
MacroGenics, Inc.
1500 East Gude Drive
Rockville, MD 20850

austinv@macrogenics.com
P. 301.354.2688
F. 301.251.5321